176 related articles for article (PubMed ID: 35583604)
1. Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL.
Hagner PR; Chiu H; Chopra VS; Colombo M; Patel N; Estevez MO; Waldman MF; Loos R; Towfic F; Gandhi AK
Clin Cancer Res; 2022 Aug; 28(15):3367-3377. PubMed ID: 35583604
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
[TBL] [Abstract][Full Text] [Related]
3. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Hagner PR; Man HW; Fontanillo C; Wang M; Couto S; Breider M; Bjorklund C; Havens CG; Lu G; Rychak E; Raymon H; Narla RK; Barnes L; Khambatta G; Chiu H; Kosek J; Kang J; Amantangelo MD; Waldman M; Lopez-Girona A; Cai T; Pourdehnad M; Trotter M; Daniel TO; Schafer PH; Klippel A; Thakurta A; Chopra R; Gandhi AK
Blood; 2015 Aug; 126(6):779-89. PubMed ID: 26002965
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB.
Solomon LA; Batista CR; DeKoter RP
Exp Hematol; 2017 Dec; 56():46-57.e1. PubMed ID: 28893618
[TBL] [Abstract][Full Text] [Related]
5. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
Matyskiela ME; Zhang W; Man HW; Muller G; Khambatta G; Baculi F; Hickman M; LeBrun L; Pagarigan B; Carmel G; Lu CC; Lu G; Riley M; Satoh Y; Schafer P; Daniel TO; Carmichael J; Cathers BE; Chamberlain PP
J Med Chem; 2018 Jan; 61(2):535-542. PubMed ID: 28425720
[TBL] [Abstract][Full Text] [Related]
6. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos.
Fedele PL; Willis SN; Liao Y; Low MS; Rautela J; Segal DH; Gong JN; Huntington ND; Shi W; Huang DCS; Grigoriadis G; Tellier J; Nutt SL
Blood; 2018 Nov; 132(20):2166-2178. PubMed ID: 30228232
[TBL] [Abstract][Full Text] [Related]
7. Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma.
Tong KI; Yoon S; Isaev K; Bakhtiari M; Lackraj T; He MY; Joynt J; Silva A; Xu MC; Privé GG; He HH; Tiedemann RE; Chavez EA; Chong LC; Boyle M; Scott DW; Steidl C; Kridel R
Clin Cancer Res; 2021 Oct; 27(19):5401-5414. PubMed ID: 34168051
[TBL] [Abstract][Full Text] [Related]
8. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
10. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.
Schafer PH; Ye Y; Wu L; Kosek J; Ringheim G; Yang Z; Liu L; Thomas M; Palmisano M; Chopra R
Ann Rheum Dis; 2018 Oct; 77(10):1516-1523. PubMed ID: 29945920
[TBL] [Abstract][Full Text] [Related]
11. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
12. Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes.
Koipally J; Renold A; Kim J; Georgopoulos K
EMBO J; 1999 Jun; 18(11):3090-100. PubMed ID: 10357820
[TBL] [Abstract][Full Text] [Related]
13. Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells.
Hung KH; Su ST; Chen CY; Hsu PH; Huang SY; Wu WJ; Chen MJ; Chen HY; Wu PC; Lin FR; Tsai MD; Lin KI
Cell Death Differ; 2016 Jul; 23(7):1175-84. PubMed ID: 26823144
[TBL] [Abstract][Full Text] [Related]
14. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH
Science; 2018 Nov; 362(6414):. PubMed ID: 30385546
[TBL] [Abstract][Full Text] [Related]
15. Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity.
Nakayama Y; Kosek J; Capone L; Hur EM; Schafer PH; Ringheim GE
J Immunol; 2017 Oct; 199(7):2388-2407. PubMed ID: 28848067
[TBL] [Abstract][Full Text] [Related]
16. Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression.
Ma S; Pathak S; Mandal M; Trinh L; Clark MR; Lu R
Mol Cell Biol; 2010 Sep; 30(17):4149-58. PubMed ID: 20566697
[TBL] [Abstract][Full Text] [Related]
17. Nuclear cereblon modulates transcriptional activity of Ikaros and regulates its downstream target, enkephalin, in human neuroblastoma cells.
Wada T; Asahi T; Sawamura N
Biochem Biophys Res Commun; 2016 Aug; 477(3):388-94. PubMed ID: 27329811
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial effects of splice variants modulate function of Aiolos.
Caballero R; Setien F; Lopez-Serra L; Boix-Chornet M; Fraga MF; Ropero S; Megias D; Alaminos M; Sanchez-Tapia EM; Montoya MC; Esteller M; Gonzalez-Sarmiento R; Ballestar E
J Cell Sci; 2007 Aug; 120(Pt 15):2619-30. PubMed ID: 17646674
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
Petzold G; Fischer ES; Thomä NH
Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
[TBL] [Abstract][Full Text] [Related]
20. [Cereblon as a primary target of IMiDs].
Ito T; Handa H
Rinsho Ketsueki; 2019; 60(9):1013-1019. PubMed ID: 31597822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
